ChemicalBook > Product Catalog >API >Fluid, Electrolyte, and Acid-Base Balance >Electrolyte Balance Pharmacology >Ibandronate sodium

Ibandronate sodium

Ibandronate sodium Structure
CAS No.
138844-81-2
Chemical Name:
Ibandronate sodium
Synonyms
Bondronat;Ibandronate sodium;IBANDRONATE USP/EP/BP;Sodium Ibandronate >IbandronicAcidSodiumSal;Ibandronic Acid Sodium Salt;Ibandronate sodiuM Bondronat;Ibandronate Sodium Anhydrous;Ibandronate sodium USP/EP/BP;(1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid monosodium salt
CBNumber:
CB31261504
Molecular Formula:
C9H24NNaO7P2
Molecular Weight:
343.23
MOL File:
138844-81-2.mol
MSDS File:
SDS
Modify Date:
2024/5/14 17:56:46

Ibandronate sodium Properties

storage temp. 2-8°C
solubility H2O: >10mg/mL
form solid
color white
Merck 14,4873
Stability Hygroscopic
InChIKey LXLBEOAZMZAZND-UHFFFAOYSA-M

SAFETY

Risk and Safety Statements

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302
Precautionary statements  P264-P270-P301+P312-P330-P501
WGK Germany  3
RTECS  SZ8563300
HS Code  29319090

Ibandronate sodium price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich(India) I5784 Ibandronate sodium salt ≥97% (NMR), solid 138844-81-2 10MG ₹12048.23 2022-06-14 Buy
Sigma-Aldrich(India) I5784 Ibandronate sodium salt ≥97% (NMR), solid 138844-81-2 50MG ₹41080.88 2022-06-14 Buy
TCI Chemicals (India) S0877 Sodium Ibandronate 138844-81-2 1G ₹8600 2022-05-26 Buy
TCI Chemicals (India) S0877 Sodium Ibandronate 138844-81-2 5G ₹9800 2022-05-26 Buy
Product number Packaging Price Buy
I5784 10MG ₹12048.23 Buy
I5784 50MG ₹41080.88 Buy
S0877 1G ₹8600 Buy
S0877 5G ₹9800 Buy

Ibandronate sodium Chemical Properties,Uses,Production

Description

ibandronate sodium (BONIVA) is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. The chemical name for ibandronate sodium is 3-(N-methyl-N-pentyl) amino-1-hydroxypropane-1,1-diphosphonic acid, monosodium salt, monohydrate with the molecular formula C9H22NO7P2Na?H20 and a molecular weight of 359.24. Ibandronate sodium is a white-to off-white powder. It is freely soluble in water and practically insoluble in organic solvents.
BONIVA is available as a white, oblong, 2.5-mg film-coated tablet for daily oral administration or as a white, oblong, 150-mg film-coated tablet for once-monthly oral administration. One 2.5-mg film-coated tablet contains 2.813 mg ibandronate monosodium monohydrate, equivalent to 2.5 mg free acid. One 150-mg film-coated tablet contains 168.75 mg ibandronate monosodium monohydrate, equivalent to 150 mg free acid. BONIVA also contains the following inactive ingredients: lactose monohydrate, povidone, microcrystalline cellulose, crospovidone, purified stearic acid, colloidal silicon dioxide, and purified water. The tablet film coating contains hypromellose, titanium dioxide, talc, polyethylene glycol 6000, and purified water.

Uses

Ibandronate sodium salt has been used to study its effect on the proliferation and ultrastructure of Leishmania and Giardia by the generation of concentration curves. It has also been used to elucidate the route by which nitrogen-containing bisphosphonates (N-BPs) enter the cytosol and inhibit their molecular target.

Pharmacokinetics

Its mechanism of action is identical to the other bisphosphonate agents. Administered daily (2.5 mg), ibandronate has been clinically shown to reduce the risk of vertebral fractures by 62%. If administered on an intermittent basis (20 mg), it reduces the risk of vertebral fractures by 50%. Ibandronate (2.5 mg daily), along with 500 mg of supplemental calcium, has been clinically shown to increase BMD in the hip (1.8%), femoral neck (2.0%), and lumbar spine (3.1%). The 150-mg formulation approved in March 2005 represents the first oral therapy for a chronic disease to be administered once monthly.

Clinical Use

Ibandronate sodium was approved in May 2003 for the treatment and prevention of osteoporosis in postmenopausal women.

Side effects

Adverse events as sociated with the injectable form ulation included arthralgia, back and abdominal pain, and hypertens ion. There is a risk of renal toxicity that is inversely related to the rate of administration of this formulation.

Metabolism

The oral bioavailability of this agent is extremely poor (0.6%) and is adversely affected by the presence of food, beverages other than water, and other medications, including calcium or vitamin D supplements and antacids. Because of the increased calcium content in mineral water, patients should not take this medication with this type of water. Drugs that inhibit gastric acid secretion (e.g., H2 antagonists and proton-pump inhibitors) actually promote ibandronate absorption. Like the others in this therapeutic class, ibandronate is not metabolized, and that which is not bound to the bone (40–50% of the absorbed dose) is eliminated renally unchanged. It does not inhibit the cytochrome P450 (CYP450) isozymes. This agent does not require any dosage adjustment for patients with hepatic impairment or mild to moderate renal impairment (creatinine clearance, >30 mL/min). Ibandronate should not be prescribed for patients with severe renal impairment (creatinine clearance, <30 mL/min).

Ibandronate sodium Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 220)Suppliers
Supplier Tel Country ProdList Advantage Inquiry
Dr. Reddy's Laboratories Ltd +91-4049002900 +91-4049002900 Hyderabad, India 165 58 Inquiry
Hetero Drugs Limited +91-4023704923 +91-4023704923 Telangana, India 296 58 Inquiry
Lee Pharma Ltd +91-9849085929 +91-9849085929 Hyderabad, India 42 58 Inquiry
Macleods Pharmaceuticals Limited +91-2266762800 +91-2266762800 Maharashtra, India 116 58 Inquiry
Orchid Pharma Ltd. (Formerly Known as Orchid Chemicals and Pharmaceuticals Ltd.) +91-4428244254 +91-4428244254 Tamil Nadu, India 28 58 Inquiry
NATCO Pharma Limited +91-9849511345 +91-9866005199 Hyderabad, India 24 58 Inquiry
Fleming Laboratories Ltd +91-9666407333 +91-9666022445 Hyderabad, India 22 58 Inquiry
Ralington Pharma +91-7948911722 +91-9687771722 Gujarat, India 1350 58 Inquiry
AKASH PHARMA EXPORTS +91-9388123451 +91-9846039283 Kerela, India 470 58 Inquiry
Athos Chemicals 91-9998858909 Gujarat, India 315 58 Inquiry
sodium [1-hydroxy-1-(hydroxy-oxido-phosphoryl)-3-(methyl-pentyl-amino) propyl]phosphonic acid Ibandronic Acid Sodium Salt (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid monosodium salt Ibandronate Sodium Anhydrous Bondronat, (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid sodium Ibandronate sodium Bondronat Ibandronate sodiuM Bondronat Sodium Ibandronate > Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) IbandronicAcidSodiumSal Phosphonicacid,[1-hydroxy-3-(methylpentylamino)propylidene]bis-,sodiumsalt(1:1) IBANDRONATE USP/EP/BP Ibandronate sodium USP/EP/BP (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonic acid monosodium salt Ibandronate sodiumQ: What is Ibandronate sodium Q: What is the CAS Number of Ibandronate sodium Q: What is the storage condition of Ibandronate sodium Q: What are the applications of Ibandronate sodium 138844-81-2 C9H22NNaO7P2 anti-osteoporosis API